オプションチェーンは、Carmellの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Carmellの市場センチメントを評価します。.

Carmell (NASDAQ:CTCX) 株価情報, オプションチェーン

Carmell Therapeutics

Carmell Corp is a bio-aesthetics company that utilizes the Carmell Secretome to support skin and hair health. Its cosmetic skincare product portfolio includes Carmell G.L.E.E and various others in pipeline such as Youth restoring formula, Ultra-brightening formula, Ultra-hydrating formula, and Rapid Recovery formula among others. The company has one operating segment, principally the business of developing and commercializing bio-aesthetics and its bone and tissue healing products.

Carmell Corp

Here&#8217;s a look at the top five trending stocks <a href="https://www.benzinga.com/general/space/24/11/42013739/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-43">on Yahoo Finance.</a> 
Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): Shares of vaccine stocks are down after President-elect Donald Trump pointed to Robert Kennedy Jr. as potentially the next Health and Human Services secretary. Trump has said <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">he would let</a> Kennedy "go wild on health" and could &#8220;do pretty much what he wants&#8221; in his administration, while Kennedy has a record of spreading falsehoods about vaccines, according to The New York Times.
Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>): Applied Materials shares are trading lower Friday following the company's fourth-quarter <a href="https://www.benzinga.com/news/earnings/24/11/41991276/applied-materials-shares-slip-despite-better-than-expected-q4-results">earnings release</a> after Thursday's closing bell. Multiple analyst firms have lowered price targets on the stock. 
Bloom Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>): Bloom Energy shares are charging higher after the energy company <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42011327/why-bloom-energy-could-reach-revenues-of-18b-next-year-says-bullish-analyst">became the latest </a>to announce a major deal to power AI data centers. Bloom Energy announced Thursday evening that it has signed a supply agreement with American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) for up to 1 gigawatt (GW) of its products, the largest commercial procurement of fuel cells in the world to date.  
Palantir Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): Palantir shares are trading at record highs Friday after the company said <a href="https://www.benzinga.com/24/11/42010539/whats-going-on-with-palantir-technologies-stock-today">it will transfer</a> its stock listing to the Nasdaq Global Select Market from the New York Stock Exchange. Palantir will begin trading as a Nasdaq-listed company on Nov. 26.
FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>): FuelCell Energy shares are slipping Friday after<a href="https://www.benzinga.com/news/guidance/24/11/42011849/restructure-and-recharge-fuelcell-cuts-workforce-plans-to-reduce-operating-costs-by-15-in-2025"> the company said </a>it will slash its workforce by 17% and reduce spending across product development, overhead and other expenses. FuelCell Energy said it needs to reduce costs and focus on core technologies due to slower-than-anticipated clean energy investments.
Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>:
<ul>
<li>Pfizer shares are down 4.59% at $24.83</li>
<li>Applied Materials shares are down 8.22% at $170.66</li>
<li>Bloom Energy shares are up 45.1% at $19.27</li>
<li>Palantir shares are up 7.54% at $63.65</li>
<li>FuelCell Energy shares are down 11.1% at $6.23 at last check on Friday. </li>
</ul>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/42009316/jeff-bezos-ex-wife-mackenzie-scott-sells-more-amazon-shares">Jeff Bezos&#8217; Ex-Wife MacKenzie Scott Sells More Amazon Shares</a></li>
</ul>
Image: Moondance from Pixabay

News

Movers

AMAT

FCEL

PLTR

Friday's Top 5 Trending Stocks: What's The Scoop On Palantir, Bloom Energy, Pfizer?

DA Davidson analyst Gil Luria maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and lowers the price target from $300 to $225.

Price Target

Analyst Ratings

NICE

DA Davidson Maintains Buy on NICE, Lowers Price Target to $225

Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares are trading lower on Friday. Following the market close on Thursday, the company reported earnings for the <a href="https://www.benzinga.com//node/41991912">2024 third-quarter</a>.
The Details: Oklo reported a loss of 8 cents per share, along with $288.5 million in cash, cash equivalents and marketable securities.
Other key pieces of financial information in the report include a year-to-date loss from operations of $37.4 million and cash used in operating activities of $24.9 million. 
For the 2024 fiscal year, the company&#8217;s sees a loss from operations is between $40 million and $50 million, with guidance for cash used in operating activities set from $35 million to $45 million.
The company announced that its Aurora Fuel Fabrication Facility reached a significant milestone during the third quarter. Specifically, it received the Department of Energy&#8217;s approval of its Conceptual Safety Design Report.
In addition, the company signed a Memorandum of Agreement with the Department of Energy in September 2024, enabling it to begin site preparations for its first powerhouse. Oklo also added two data center customers to its pipeline. 
&#8220;The world is now recognizing nuclear's role in powering that future. I'm confident we'll look back on 2024 as the turning point in our mission to deliver clean, reliable, and affordable energy for all. Momentum is building every week—regulators are modernizing, bipartisan support is growing, and some of the most influential companies are investing heavily in the space,&#8221; said Jacob Dewitte, Co-Founder and CEO of Oklo.
Related Link: <a href="https://www.benzinga.com/news/earnings/24/11/42000144/alibaba-applied-materials-and-3-stocks-to-watch-heading-into-friday">Alibaba, Applied Materials And 3 Stocks To Watch Heading Into Friday</a>
OKLO Price Action: At the time of writing, Oklo stock is trading 22.3% at $18.56, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Courtesy of Oklo, Inc.

OKLO

What's Going On With Oklo Stock Friday?

On Thursday, Halozyme Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) submitted a non-binding proposal to Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) to acquire the German company for 11.00 euros per share in cash, implying a fully diluted <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41989694/halozyme-confirms-proposal-to-combine-with-evotec-for-11-00-per-share-in-an-all-cash-transaction" rel="noreferrer noopener">equity value of 2.0 billion euros</a> (around $2.11 billion).
The proposal represents a premium of 109% to Evotec&#8217;s undisturbed share price on&nbsp;October 15, 2024, the day before Triton Partners&#8217; initial accumulation of Evotec shares.
Evotec&nbsp;<a target="_blank" href="https://www.evotec.com/en/about-us/evotec" rel="noreferrer noopener">offers</a> drug discovery and development services to several biotech and pharmaceutical companies.
&#8220;The combination of Halozyme and Evotec would diversify and extend Halozyme revenue and EBITDA growth and durability well into the next decade and beyond,&#8221; said&nbsp;Helen Torley, president and chief executive officer of Halozyme.
Halozyme said its strong cash flow would enable ongoing investments in Evotec&#8217;s early-stage programs and new technologies.
The proposed&nbsp;combination&nbsp;is expected to significantly expand and diversify Halozyme&#8217;s revenue and EBITDA over the next decade. The combined technology offerings would open up new partnership opportunities and program expansions.
Earlier this week, a Bloomberg report highlighted that private equity firm Triton Partners&nbsp;was also considering acquiring Evotec. In an SEC filing, Evotec&nbsp;reported&nbsp;that Triton had acquired a 9.99% stake in the company via several <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41882329/private-equity-triton-partners-takes-around-10-stake-in-evotec-reportedly-mulls-potential-takeover-deal" rel="noreferrer noopener">open-market transactions</a>.
During its second-quarter earnings release, Evotec&nbsp;disclosed it identified a headcount reduction potential of approximately 400 roles (7% of the&nbsp;workforce) across the global footprint and a reduction of the physical footprint by surrendering <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40376143/bristol-myers-german-partner-evotec-plans-layoffs-cites-challenging-revenues-profitability" rel="noreferrer noopener">certain lease agreements</a>.
Evotec&nbsp;exited gene therapy and closed a site in Orth, Austria. It also shut down chemistry activities in Lyon, France, and separated a manufacturing facility in Halle/Westphalia, Germany.
Recently, Halozyme reported third-quarter 2024 revenue of $290.1 million, compared to&nbsp;$216.0 million&nbsp;in the third quarter of 2023.
While announcing its third quarter results, Halozyme raised the fiscal year 2024 adjusted EPS guidance to $4.00-$4.20 from $3.65-$4.05 (current consensus $4.15) and revenue guidance to $970 million—$1.02 billion from $935 million—$1.015 billion (current <a href="https://www.benzinga.com/pressreleases/24/10/n41663735/halozyme-reports-third-quarter-2024-financial-and-operating-results" target="_blank" rel="noreferrer noopener">consensus of $1.003 billion</a>).
Evotec <a href="https://www.benzinga.com//node/41994208">responded today</a> that it would thoroughly evaluate this expression of interest, determine the appropriate next steps, and communicate its decisions to the capital market in compliance with legal requirements.
Price Action: HALO stock is down 14.8% at $45.97 and EVO stock is up 8.43% at $5.53 at last check Friday.
Image via Pexels
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers" target="_blank" rel="noreferrer noopener">European And US Vaccine Stocks Are Under Pressure &#8211; Here&#8217;s Why</a></li>
</ul>

Biotech

Equities

Health Care

Trading Ideas

General

HALO

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Amazon.Com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares are moving lower on Friday after Third Point reported that it decreased its stake in the company. Here&#8217;s what <a href="https://www.benzinga.com//node/41997557">you need to know</a>.
What To Know: In the 13F filing with the Securities and Exchange Commission, Third Points disclosed that it decreased its stake in Amazon by 27% from 5,100,000 shares to 3,700,000 shares.
Aside from Amazon, Third Point disclosed several other notable cuts to its holdings in different companies. It reported that it reduced its stake in Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) by 45% and 50% respectively. 
Specifically, it now owns 870,000 shares in Microsoft where it previously held 1,580,000 shares. In Meta, Third Point cut its shares from 1,100,000 to 545,000.
How To Buy Amazon Stock 
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Amazon.com's case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also: <a href="https://www.benzinga.com/tech/24/11/42008585/why-super-micros-survival-may-hinge-on-nvidia-earnings-nasdaq-deadline">Why Super Micro&#8217;s Future May Hinge On Nvidia Earnings, Nasdaq Deadline (UPDATED)</a>
AMZN Price Action: At the time of publication, Amazon stock is trading 4.27% lower at $202.49, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Shutterstock

Startups

AMZN

MSFT

What's Going On With Amazon Shares Friday?

DA Davidson analyst Thomas Diffely maintains Kulicke &amp; Soffa Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) with a Buy and lowers the price target from $65 to $60.

KLIC

DA Davidson Maintains Buy on Kulicke & Soffa Indus, Lowers Price Target to $60

Insider Trades

Proficient Auto Logistics Form4 Filing Shows CEO Richard D Odell Bought 54,000 Shares At An Average Price Of $9.20/Share

The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) provided a look at multi-year guidance, which surprised analysts and resulted in price targets being raised after the company&#8217;s <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">fourth-quarter financial results. </a>
The Disney Analysts:
<ul>
<li>Guggenheim analyst Michael Morris maintained a Buy rating on Disney and raised the price target from $110 to $130.</li>
<li>Macquarie analyst Tim Nollen maintained a Neutral rating and raised the price target from $91 to $110.</li>
<li>Goldman Sachs analyst Michael Ng maintained a Buy rating and raised the price target from $125 to $135.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/11/41953395/disney-q4-earnings-preview-disney-profitability-deadpool-box-office-success-top-items-to-watch">Disney Q4 Earnings Preview: Disney+ Profitability, Deadpool Box Office Success Top Items To Watch</a>
Guggenheim on DIS: Multi-year guidance provided by Disney could help instill confidence in a path for long-term growth, Morris said in a new investor note.
The analyst said fourth-quarter results saw direct-to-consumer profit come in ahead of estimates with linear networks lagging.
"Key incremental item is the detailed, multi-year financial guidance, which includes FY25 EPS growth ahead of consensus and acceleration to double-digit growth in 2026 and 2027," Morris said.
The analyst said entertainment, DTC and studio growth are expected to offset the continued pressure on linear networks.
"We see ESPN Flagship launch, consolidated entertainment growth, parks profit expansion and succession clarity as core components of the BUY thesis into 2025."
Macquarie on DIS: There was a lot to like in Disney's fourth-quarter results and guidance, Nollen said in a new investor note.
"Disney's F4Q report contained positive and detailed guidance for FY25-27 that speak to its long-term potential," Nollen said.
DTC profitability, the success of big blockbuster films, and advertising stability were highlights for the analyst in the fourth quarter.
The analyst also said Disney's guidance was richer than usual.
While the quarter was strong, the analyst remains Neutral, given near-term risks and concerns about the stock&#8217;s valuation, with shares trading at 20x PE and 12x FY25 EV/EBITDA.
Nollen is concerned that the ESPN DTC Flagship launch could include trade-offs with linear subscribers.
"Disney is the one traditional media company that we can be confident will transition successfully to streaming. The positive detailed guidance is encouraging, and sentiment could carry the stock."
Goldman Sachs on DIS: Theme park recovery, DTC strength and the multi-year outlook were highlights in the fourth quarter for Ng.
"DIS provided a 3-year outlook that exceeded even our above-consensus expectations," Ng said.
The analyst said the guidance for fiscal 2025, 2026 and 2027 was better than expected and shows strength across several key segments.
"DIS expects its F2025 results to reflect progression in profitably scaling its streaming businesses with attractive margins and continued investments to grow its Experiences business."
The analyst is watching the launch of ESPN Flagship, upcoming movies like "Moana 2" and "Mufasa,&#8221; the company's upcoming theme park expansions and new cruise ships for future growth.
"We are Buy-rated on DIS as we believe the company is a high-quality EPS compounder."
DIS Price Action: Disney stock is up 3.6% to $113.07 on Friday versus a 52-week trading range of $83.91 to $123.74. Disney stock is up 25% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41999904/disney-ceo-bob-iger-slams-the-brakes-on-new-ma-amid-comcasts-cable-spinoff-we-dont-need-more-assets-to-compete-in-todays-disruptive-media-landscape">Bob Iger Slams The Brakes On New M&amp;A Amid Comcast&#8217;s Cable Spinoff: Disney Doesn&#8217;t &#8216;Really Need More Assets&#8217; To Compete</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Entertainment

Reiteration

Sports

Disney Q4 Report Had 'A Lot To Like': Analyst Calls It A 'High-Quality' Profit Growth Performer

RBC Capital analyst Rishi Jaluria reiterates NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Outperform and maintains $260 price target.

RBC Capital Reiterates Outperform on NICE, Maintains $260 Price Target

WIIM

IMNM

Immunome shares are trading lower on continued weakness after the company on Wednesday reported worse-than-expected Q3 EPS results.

DA Davidson analyst Manuel Navas maintains Provident Finl Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFS#NYSE">PFS</a>) with a Buy and raises the price target from $24 to $27.

DA Davidson Maintains Buy on Provident Finl Servs, Raises Price Target to $27

RBC Capital analyst Elvira Scotto reiterates Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) with a Sector Perform and maintains $19 price target.

RBC Capital Reiterates Sector Perform on Plains All American, Maintains $19 Price Target

Loop Capital analyst Alan Gould maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and raises the price target from $120 to $125.

Loop Capital Maintains Buy on Walt Disney, Raises Price Target to $125

RBC Capital analyst Sabahat Khan reiterates Tetra Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>) with a Outperform and maintains $52 price target.

TTEK

RBC Capital Reiterates Outperform on Tetra Tech, Maintains $52 Price Target

PepsiCo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) shares are trading lower by 3.75% to $158.97 Friday afternoon. Shares of beverage and packaged food stocks are trading lower after President-elect Donald Trump indicated he would nominate Robert F. Kennedy Jr. to <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">lead the HHS</a>.
What To Know: Kennedy's history of criticizing corporate influence on public health has raised concerns about potential regulatory shifts targeting key sectors of PepsiCo&#8217;s diversified business.
As a global leader in beverages and snacks, PepsiCo's portfolio includes sugary soft drinks, such as Pepsi and Mountain Dew, alongside snacks like Doritos and Lay's, as well as healthier offerings under brands like Quaker and Naked Juice. 
Analysts warn that Kennedy's stance on the &#8220;industrial food complex&#8221; could lead to stricter rules on sugar content, marketing practices, and nutritional labeling.
With U.S. consumers already <a href="https://www.benzinga.com/general/biotech/24/07/39656549/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo">gravitating toward healthier options</a>, any heightened regulatory scrutiny on sugary beverages and processed snacks could pressure PepsiCo's core businesses. In addition, possible restrictions on marketing to children, a key demographic for many of its products, could further impact growth.
Read Also: <a href="https://www.benzinga.com/news/retail-sales/24/11/42008180/october-retail-sales-top-expectations-as-us-consumers-increase-tech-spending">October Retail Sales Top Expectations As US Consumers Increase Tech Spending</a>
<h2 class="wp-block-heading">How To Buy PEP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in PepsiCo&#8217;s case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PEP has a 52-week high of $183.39 and a 52-week low of $158.03.

Why Pepsi Stock Is Falling

Loop Capital analyst Jeffrey Stevenson maintains BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) with a Buy and raises the price target from $18 to $20.

Loop Capital Maintains Buy on BrightView Hldgs, Raises Price Target to $20

DA Davidson analyst Michael Shlisky maintains Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) with a Buy and maintains $82 price target.

DA Davidson Maintains Buy on Miller Industries, Maintains $82 Price Target

RBC Capital analyst Luca Issi reiterates bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Sector Perform and maintains $4 price target.

BLUE

RBC Capital Reiterates Sector Perform on bluebird bio, Maintains $4 Price Target

Maxim Group analyst Jason McCarthy maintains Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) with a Buy and raises the price target from $60 to $110.

BLTE

Maxim Group Maintains Buy on Belite Bio, Raises Price Target to $110

In the tech world, few <a href="https://www.benzinga.com/markets/24/10/41457050/bill-gates-once-said-he-was-so-jealous-of-apples-steve-jobs-and-labeled-him-a-genius-and-wizard-no-o">rivalries are as legendary</a> as that between Apple's Steve Jobs and <a href="https://www.benzinga.com/general/education/24/10/41580000/bill-gates-turns-69-5-things-you-might-not-know-about-microsoft-co-founder">Microsoft's Bill Gates</a>. The two pioneers changed the personal computer industry and how we use technology by pushing the envelope in their special ways for decades. However, when asked about his relationship with Gates in a rare joint interview, Jobs didn&#8217;t respond with competitiveness or rivalry – instead, he quoted a line from a Beatles song.
Don't Miss:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
During the 2007 <a href="https://www.youtube.com/watch?v=wvhW8cp15tk">interview</a>, Jobs and Gates reminisced about their long history in the industry. They laughed, remembering their early years when they were frequently the youngest in the room. Gates noted how it was always wonderful to see someone like Jobs persevere through the many challenges and trends offered by the rapidly changing computer sector.&nbsp;
Jobs, known for his passion for music, quoted The Beatles' reflective line: "You and I have memories longer than the road that stretches out ahead,&#8221; before adding, &#8220;And that&#8217;s clearly true here.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When Steve Jobs was asked about his relationship with competitor and business rival, Bill Gates, he answered with a lyric from this reflective Beatles song: <a href="https://t.co/CovfClpMim">pic.twitter.com/CovfClpMim</a>
&mdash; The Beatles Earth (@BeatlesEarth) <a href="https://twitter.com/BeatlesEarth/status/1856357686956237143?ref_src=twsrc%5Etfw">November 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
The lyric from The Beatles' "Two of Us" <a href="https://www.youtube.com/watch?v=cLQox8e9688">song</a> perfectly captured the sentiment. For all their competition, Jobs and Gates shared a deep mutual respect. The song is about friendship, shared memories and a sense of journey – and that's exactly how Jobs saw his connection with Gates. After all, they'd both been through the ups and downs of building billion-dollar companies, watching trends come and go and surviving the intense pressures of leading groundbreaking tech firms.
It was a moment that showed the softer side of their relationship and that despite being rivals, Jobs and Gates weren't just competing tech CEOs – they were two individuals who'd shared a unique journey in an industry they helped to shape. Their antagonism had subsided into camaraderie based on mutual knowledge of what it required to get to where they were, shared experiences and the <a href="https://www.benzinga.com/personal-finance/24/10/41340693/bill-gates-saved-rival-apple-from-bankruptcy-by-investing-150-million-steve-jobs-thanked-him-pub">rare act of cooperation</a>.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Back in the late '70s and early '80s, Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was working hard to get its personal computers into homes, schools and offices, aiming to make computers friendly, accessible and even stylish. Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), on the other hand, was all about software under Gates&#8217; direction. Gates aimed to install Microsoft&#8217;s operating system on as many machines as possible, including IBM, Apple&#8217;s main rival. And a long-standing rivalry was sparked by this action.&nbsp;
Microsoft's Windows operating system, <a href="https://www.benzinga.com/tech/24/11/41872487/bill-gates-introduced-windows-41-years-ago-today-heres-how-much-youd-have-if-you-invested-1000-in-microsoft-when-it-went-public">introduced in 1983</a>, was strikingly similar to Apple's Mac OS and Jobs was not happy about it. He famously accused Gates of copying Apple&#8217;s interface, saying that Microsoft had no shame in borrowing ideas.
Ultimately, this brief Beatles reference from Jobs was a reminder of the humanity behind the industry giants. For those who grew up with either an Apple device or Microsoft software – most of us have used both – their partnership and rivalry have always felt like a part of our own experience with technology.
Read Next:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>

AAPL

When Asked About His Business Rivalry With Bill Gates, Steve Jobs Replied With A Beatles Lyric From This Reflective Song

Carmell CEO buys shares worth over $15.5k - filing

Carmell looks to sell Axolotl Biologix

Carmell Corporation files to sell 1.33M for holders

Carmell Corporation files to sell 1.33M shares for holders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the first quarter of 2024.<ul><li>Carmell Therapeutics reported earnings per share of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ctcx-stock-earnings-carmell-therapeutics-for-q1-of-2024/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the fourth quarter of 2023.<ul><li>Carmell Therapeutics reported earnings per share of $1.35.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ctcx-stock-earnings-carmell-therapeutics-for-q4-of-2023/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023

Carmell appoints Kendra Bracken-Ferguson as CEO

An update from Carmell Therapeutics (CTCX) is now available. Carmell Corporation has announced a major leadership change with Rajiv S. Shukla stepp...

Carmell Therapeutics Announces CEO Transition and New Leadership Incentives

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the second quarter of 2024.<ul><li>Carmell Therapeutics reported earnings per share of -16 cents.</li><li>The company reported revenue of $12,320.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ctcx-stock-earnings-carmell-therapeutics-for-q2-of-2024/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q2 2024

CTCX

Management

Press Releases

Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

Carmell to Host Investor Webinar, "Unveiling the Secretome: On the Eve of Product Launch" Featuring Key Opinion Leaders in the Medical Aesthetics Field

Comments

Carmell

Carmell (CTCX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル